Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Genflow Biosciences Plc LSE:GENF London Ordinary Share GB00BP2C3V08 ORD GBP0.0003
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10 -4.26% 2.25 129,409 15:54:46
Bid Price Offer Price High Price Low Price Open Price
2.20 2.30 2.35 2.25 2.35
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 7
Last Trade Time Trade Type Trade Size Trade Price Currency
16:13:54 O 882 2.2559 GBX

Genflow Biosciences (GENF) Latest News

More Genflow Biosciences News
Genflow Biosciences Investors    Genflow Biosciences Takeover Rumours

Genflow Biosciences (GENF) Discussions and Chat

Genflow Biosciences Forums and Chat

Date Time Title Posts
12/1/202311:30Genflow Biosciences plc 202281
06/12/202209:56Old age a thing of the past?34
15/4/202210:31US SEC indicts key shareholder-
01/2/202211:45Welcome3

Add a New Thread

Genflow Biosciences (GENF) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:13:552.2688219.90O
15:58:042.2666214.93O
15:57:302.26881.99O
15:54:292.206,634145.95O
15:50:242.201,34929.68O
View all Genflow Biosciences trades in real-time

Genflow Biosciences (GENF) Top Chat Posts

Top Posts
Posted at 14/12/2022 07:04 by moneymunch
PRESS RELEASE

14 December 2022



Genflow Biosciences Plc

("Genflow" or "the Company")



Intellectual property (IP) Portfolio addition:

Patent submitted for transformational treatment of non-alcoholic fatty liver disease (NAFLD)



Genflow (LSE: GENF), would like to announce that it has filed a new patent application with the United States Patent and Trademark Office ("USPTO") that relates to variants of Sirtuin-6 ("SIRT6"), and the gene variant's therapeutic uses for the treatment of two disorders involving the liver: non-alcoholic fatty liver disease ("NAFLD"), and non-alcoholic steatohepatitis ("NASH"), an advanced form of NAFLD (the "Application").

Genflow holds the exclusive licence for this application through Genflow Biosciences SRL (the Company's Belgian subsidiary).

NAFLD affects approximately 20% of the general population, meaning this is a significant area for Genflow to be present in the research space with the potential to change the lives of many disorder sufferers. The number of people with NASH, I expected to rise dramatically in future years due to growing obesity rates in developed nations.

In the past decade, large drugmakers including Allergan, Gilead and Novartis, have spent billions of dollars acquiring or licensing medicines designed to treat NASH.

Dr Eric Leire, Founder and CEO of Genflow, said: "I'm proud of the tremendous progress Genflow has achieved in filing this new patent, and we look forward to adding to the expanding body of knowledge about ageing, liver diseases and bolstering our ever-growing patent portfolio."

IP Portfolio Update: SIRT6 Age-related cases

The international patent application for the use of SIRT6 in the treatment and prevention of age-related diseases has received its first positive review from the Patent Cooperation Treaty Examiner

The PCT Examiner has confirmed the novelty and inventiveness of Genflow's filing which represents the first significant step on the path to the patent, [for which Genflow already has an exclusive license,] being granted.

Posted at 05/12/2022 13:14 by felchandbart
Looking strong. Longevity - a great sector to be involved with. And GENF is certainly stirring into life by the looks of things:)
Posted at 30/11/2022 15:58 by felchandbart
Another great find, moneymunch. It's great to still be able to invest in this stock at such an incredibly low price.
Posted at 28/11/2022 15:04 by moneymunch
The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...

To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D.

 

But even the companies regarded as the cream-of-crop are at a disadvantage…

They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.”

Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s overexpression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”.

This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs…

If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement.

Altos Labs opened only a few months ago, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.

It stands to reason that the mega-tech startup would team up with or outright buy Genflow Biosciences, launching its extremely undervalued share price to match, or exceed, its peer group.

Consider that on mere rumors of acquisition for their LIDAR IP, Microvision’s (MVIS) share price exploded almost 300% in less than 2 weeks last year.

Now imagine the sudden news that a Bezo’s backed company set on discovering the formula for immortality is acquiring or partnering with a little-known European biotech start-up with a share price of only 2p

 

News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year.

This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another. 

https://clearcapitalmarkets.co.uk/biotech-opinion-joe-neighbour/?gclid=EAIaIQobChMInZjjq4TP-wIVhLTtCh3iWQGBEAAYASAAEgIBGfD_BwE

Posted at 01/8/2022 13:53 by dave4545
2.75-2.755p spread

So now you can buy size at the bid price and a full penny lower than recent director buys.

Posted at 12/7/2022 08:59 by tomboyb
GENF is in the position where no funding is required -

Down from header 13p to 2p is a good entry imo -

Posted at 12/7/2022 08:45 by dave4545
It was 2.35p mid price yesterday, when I saw that trade today I rushed to see if smaller could get that price still but not a bean offered online so it's going to shift.

Should have took a starter yesterday as a base.

Took the NMS 30k at 2.5p, mm wanted 3p for 100k when 2.5p offer greedy or what

Posted at 12/7/2022 07:56 by tomboyb
Buzz, I think GENF have run out of sellers -

Buying and adding a few Biotech -

Posted at 11/7/2022 08:08 by manual dexterity
The difference here having looked at both CIZ and GENF is that CIZ may need funds. GENF has no requirement for fund for the foreseeable future. I do think this has been hit pretty hard, so a decent punt at these levels.
Posted at 09/6/2022 13:31 by deadly nightshade
Any idea if we have a big seller here as share price is crashing? Someone looks to be off loading big time by the look of the trades?
Genflow Biosciences share price data is direct from the London Stock Exchange
Your Recent History
LSE
GENF
Genflow Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230127 21:36:42